Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Investor Investigation Concerning Potential Securities Laws Violations Announced

If you purchased shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Aegerion Pharmaceuticals
Affected Securities: 
NASDAQ: AEGR

November 01, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares over potential securities laws violations by Aegerion Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) concerning whether a series of statements by Aegerion Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) rose from $12.04 per share to as high as $97.24 per share in October 2013.

Then in November 2013, news reports revealed that Aegerion Pharmaceuticals, Inc. received an FDA Warning Letter (the, "Warning Letter") in connection with statements the Company's CEO made regarding JUXTAPID capsules, during broadcast interviews on CNBC's television show, "Fast Money," that aired on June 5, 2013, and October 31, 2013. Then on January 9, 2014, Aegerion Pharmaceuticals, Inc. reported its preliminary 2013 Net product sales, its outlook for 2014 and other business updates. Among other things, Aegerion Pharmaceuticals, Inc. announced that it has received a subpoena from the United States Department of Justice, represented by the U.S. Attorney’s Office in Boston, MA, requesting documents regarding the Company’s marketing and sale of JUXTAPID in the U.S.

In February 2014 Aegerion Pharmaceuticals, Inc. reported its fourth quarter and full year 2013 financial results. Aegerion Pharmaceuticals, Inc. reported that its annual Total Revenue rose to $48.55 million in 2013 while its Net Loss increased from $62.27 million in 2012 to $63.36 million in 2013.

In May 2014 Aegerion Pharmaceuticals, Inc. announced its first quarter 2014 financial results. Aegerion Pharmaceuticals, Inc reported that its first quarter Revenue in 2014 was $26.97 million with a first quarter Net Loss of $15.78 million.

In July 2014 Aegerion Pharmaceuticals, Inc. announced its second quarter 2014 financial results. For the second quarter Aegerion Pharmaceuticals, Inc reported that its second quarter Revenue rose from $64.49 million in 2013 to $36.01 million in 2014 and that its respective second quarter Net Loss declined from $18.90 million in 2013 to $9.62 million in 2014.

Then on October 30, 2014 Aegerion Pharmaceuticals, Inc. announced its financial results and business highlights for the third-quarter of 2014. Among other things, Aegerion Pharmaceuticals, Inc. also issued its 2014 and 2015 financial guidance.

Shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) declined to as low as $19.10 per share on October 31, 2014.